胰腺癌放疗研究进展  

Progresses on radiotherapy in pancreatic cancer

作　　者：卢珂(综述)[1] 邓清华(审校)[1] 

机构地区：[1]浙江省肿瘤医院放疗科十病区,杭州310022

出　　处：《国际肿瘤学杂志》2010年第10期771-773,共3页Journal of International Oncology

摘　　要：近年来的研究表明，对于可手术切除胰腺癌患者，不论手术切缘状况、原发肿瘤大小、有无淋巴结转移、肿瘤分化程度等，均能从术后辅助放化疗中获益；术前新辅助放化疗的多项Ⅱ期临床研究均提示治疗耐受性良好。对于局部晚期不能手术切除胰腺癌患者的治疗目前尚无金标准，但以吉西他滨为基础的化疗或以吉西他滨为基础的放化疗与最佳支持对症治疗相比延长了总生存率。Recent researches have shown that reseetable pancreatic cancer can benefit from post-oper- ative adjuvant chemoradiation, regardless its surgical margins, tumor size, lymph node involvement and the lev- el of cell differentiation. Several phase ]] clinical trials indicated a gc^od tolerance to preoperative chemoradi- ation. Although there is no gold standard for treating locally advanced unresectable pancreatic cancer, gemcit- abine-based chemotherapy or chemoradiation therapy can increase survival rate compared with best supportive care.

关 键 词：胰腺肿瘤 放射疗法 

分 类 号：R979.5[医药卫生—药品]